Serum-autoantibodies for discovery of prostate cancer specific biomarkers

Prostate

Volumn 72, Issue 4, 2012, Pages 427-436

  Massoner, Petra ^a   Lueking, Angelika ^b   Goehler, Heike ^b   Höpfner, Annabel ^b   Kowald, Axel ^b   Kugler, Karl G ^c   Amersdorfer, Peter ^d   Horninger, Wolfgang ^a   Bartsch, Georg ^a   Schulz Knappe, Peter ^b   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PROTAGEN AG   (Germany)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d DiagnoNET   (Austria)

Author keywords

autoantibody; autoantigen; biomarker; diagnostics; prostate cancer; TTLL12

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; COMPLEMENTARY DNA; NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN; RNA;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BIOINFORMATICS; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; HUMAN; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856040057     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21444     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Boyle P, Levin B,. World Cancer Report 2008. Lyon: World Health Organization: International Agency for Research on Cancer; 2008.
3. United Nations. World Population Aging 2009; in: United Nations (ed): ST/ESA/SER.A/295, Population Division, Department of Economic and Social Affairs, United Nations, 2009.
4. Ulmert D, O'Brien MF, Bjartell AS, Lilja H,. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009; 6: 384-391.
5. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G,. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006; 164: 376-384. (Pubitemid 44297346)
6. Loeb S, Catalona WJ,. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249: 30-39. (Pubitemid 46437279)
7. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS,. Cancer surveillance series: Interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-1024. (Pubitemid 29293040)
8. Makarov DV, Loeb S, Getzenberg RH, Partin AW,. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139-151.
9. Haese A, Graefen M, Palisaar J, Huland E, Huland H,. Serum markers for early detection and staging of prostate cancer. Status report on current and future markers. Urologe A 2003; 42: 1172-1187. (Pubitemid 37176290)
10. Hessels D, Schalken JA,. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255-261.
11. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
12. Pardoll D,. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-839. (Pubitemid 37174548)
13. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, Robertson JF,. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 2006; 6: 1215-1223. (Pubitemid 44304689)
14. Lin HS, Talwar HS, Tarca AL, Ionan A, Chatterjee M, Ye B, Wojciechowski J, Mohapatra S, Basson MD, Yoo GH, Peshek B, Lonardo F, Pan CJ, Folbe AJ, Draghici S, Abrams J, Tainsky MA,. Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2396-2405. (Pubitemid 351196373)
15. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF,. Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure. Thorax 2008; 63: 228-233. (Pubitemid 351373718)
16. Bradford TJ, Wang X, Chinnaiyan AM,. Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006; 24: 237-242.
17. Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A,. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008; 7: 600-611. (Pubitemid 351472469)
18. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P,. Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence and mortality. BJU Int 2008; 101: 809-816. (Pubitemid 351347736)
19. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G,. Prostate cancer screening in the Tyrol, Austria: Experience and results. Eur J Cancer 2000; 36: 1322-1335.
20. Horn S, Lueking A, Murphy D, Staudt A, Gutjahr C, Schulte K, Konig A, Landsberger M, Lehrach H, Felix SB, Cahill DJ,. Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 2006; 6: 605-613. (Pubitemid 43208040)
21. Lueking A, Huber O, Wirths C, Schulte K, Stieler KM, Blume-Peytavi U, Kowald A, Hensel-Wiegel K, Tauber R, Lehrach H, Meyer HE, Cahill DJ,. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics 2005; 4: 1382-1390. (Pubitemid 41448724)
22. Feyen O, Lueking A, Kowald A, Stephan C, Meyer HE, Gobel U, Niehues T,. Off-target activity of TNF-alpha inhibitors characterized by protein biochips. Anal Bioanal Chem 2008; 391: 1713-1720.
23. Statnikov A, Aliferis CF, Tsamardinos I, Hardin D, Levy S,. A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics 2005; 21: 631-643. (Pubitemid 40424789)
24. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
25. Huang da W, Sherman BT, Lempicki RA,. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
26. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA,. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
27. Bussow K, Cahill D, Nietfeld W, Bancroft D, Scherzinger E, Lehrach H, Walter G,. A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Res 1998; 26: 5007-5008. (Pubitemid 28491184)
28. Wasylyk C, Zambrano A, Zhao C, Brants J, Abecassis J, Schalken JA, Rogatsch H, Schaefer G, Pycha A, Klocker H, Wasylyk B,. Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy. Int J Cancer 2010; 127: 2542-2553.
29. Gumaa KA, MacLeod RM, McLean P,. The pentose phosphate pathway of glucose metabolism. Influence of a growth-hormone-secreting pituitary tumour on the oxidative and non-oxidative reactions of the cycle in liver. Biochem J 1969; 113: 215-220.
30. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, Glantz MJ, Jaeckle KA, Biran H, Lesser M, Palsen WA, River ME, Posner JB,. Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29: 241-251.
31. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA,. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010; 16: 681-690.
32. Gambichler T, Rotterdam S, Radkowski K, Altmeyer P, Kreuter A,. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions. Am J Clin Pathol 2009; 131: 710-714.
33. Blumcke I, Muller S, Buslei R, Riederer BM, Wiestler OD,. Microtubule-associated protein-2 immunoreactivity: A useful tool in the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol 2004; 108: 89-96. (Pubitemid 39136293)
34. Krishnan C, Higgins JP, West RB, Natkunam Y, Heerema-McKenney A, Arber DA,. Microtubule-associated protein-2 is a sensitive marker of primary and metastatic neuroblastoma. Am J Surg Pathol 2009; 33: 1695-1704.
35. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M,. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003; 10: 1777-1782.
36. van der Weyden L, Adams DJ,. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776: 58-85. (Pubitemid 47332074)
37. Sherwood V, Manbodh R, Sheppard C, Chalmers AD,. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008; 19: 1772-1782. (Pubitemid 351805128)
38. Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, Bouman D, Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GC, Chan LC, Squire J, Scherer SW, Hitzler JK,. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001; 28: 220-221. (Pubitemid 32626023)
39. Hormigo A, Dalmau J, Rosenblum MK, River ME, Posner JB,. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994; 36: 896-902. (Pubitemid 24370930)
40. Huang CS, Shi SH, Ule J, Ruggiu M, Barker LA, Darnell RB, Jan YN, Jan LY,. Common molecular pathways mediate long-term potentiation of synaptic excitation and slow synaptic inhibition. Cell 2005; 123: 105-118. (Pubitemid 41414532)
41. Crawford ED, Abrahamsson PA,. PSA-based screening for prostate cancer: How does it compare with other cancer screening tests? Eur Urol 2008; 54: 262-273.
42. Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, Labaer J,. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011; 10: 85-96.
43. Colasanti T, Delunardo F, Margutti P, Vacirca D, Piro E, Siracusano A, Ortona E,. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 2009; 212: 3-9.
44. Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH,. Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002; 35: 79-86. (Pubitemid 34678725)
45. Scofield RH,. Autoantibodies as predictors of disease. Lancet 2004; 363: 1544-1546. (Pubitemid 38596835)
46. Liu SY, Chen YT, Tseng MY, Hung CC, Chiang WF, Chen HR, Shieh TY, Chen CH, Jou YS, Chen JY,. Involvement of microtubule-associated protein 2 (MAP2) in oral cancer cell motility: A novel biological function of MAP2 in non-neuronal cells. Biochem Biophys Res Commun 2008; 366: 520-525.